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Critically ill patientsIntroduction: Critically ill patients with acute kidney injury (AKI) present high mortality rates. The mag-
nitude of inﬂammatory response could determine the prognosis of such patients. Continuous renal
replacement therapy (CRRT) may play an important role in removing inﬂammatory mediators in patients
with AKI.
Aim: To investigate whether the magnitude of inﬂammatory mediator’s removal is associated with mor-
tality among critically ill patients on CVVHDF, a CRRT modality.
Methods: This study consisted of 64 critically ill patients requiring CVVHDF. Plasma levels of C3a, TNF-a,
IL-10, IL-6, IL-1b, sTNFRI and sTNFRII were determined by enzyme-linked immunosorbent assay (ELISA)
at the beginning of CVVHDF and after 24 h (outlet). Clearance of cytokines during the ﬁrst 24 h of
CVVHDF was calculated. Clinical and laboratory data were acquired from patient’s records data.
Results: Mean age of patients requiring CVVHDF was 63 years, 67.2% were men and 87.3% were Cauca-
sian. Thirty-ﬁve (35) patients (54.7%) died. Comparing non-survivors with the group of survivors we
observed higher incidence of sepsis (68.6 versus 37.9%, p < 0.05), higher APACHE II score (34.8 ± 7.6 ver-
sus 29.2 ± 7.1, p < 0.05) and higher lactate levels (23.2 ± 17.6 versus 16.4 ± 6.6, p < 0.05). According to the
inter-tertile range of TNF-a clearance (ITR1 (<0.54); ITR2 (0.54–2.93); ITR3 (>2.93)) we found that those
patients with higher TNF-a removal by RRT (ITR3) had a better survival. Multivariable analysis showed
that lower clearance of TNF-a remained independently associated with high mortality after adjustment
for sex, age, use of vasoactive drugs, APACHE II score sepsis, creatinine and lactate before CVVHDF (HR:
0.179, 95% IC: 0.049–0.661, p < 0.01).
Conclusion: The attenuation of inﬂammatory response may be related to the lower mortality observed on
those patients with higher TNF-a removal by CVVHDF.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
It is estimated that more than 30% of intensive care unit (ICU)
patients develop acute kidney injury (AKI), often accompanied by
clinical, surgical or traumatic complications, usually with multiple
organ and system dysfunction [1,2]. The most frequent cause of
AKI is sepsis, a primary cause of increased morbidity and mortality,
especially in ICU patients [3,4]. Even with the latest advances and
innovations in renal replacement therapy (CRRT), the mortality ofICU patients remains high [5,6]. It is suggested that this treatment
modality, in comparison with conventional hemodialysis, provides
better cardiovascular tolerance associated with minimal variability
of plasma osmolality, better metabolic control, more efﬁcient cor-
rection of acid-base and electrolyte disturbances, and slow and
unlimited ﬂuid removal that facilitates the administration of par-
enteral nutrition and ﬂuids in critically ill patients with AKI [7].
Serum levels of inﬂammatorymediators are increased inpatients
with AKI, regardless of its cause. Pro- and anti-inﬂammatory medi-
ators play important roles in regulating the immunologic response
which mediates the severity of the disease and its complications
[8]. The increased plasma levels of pro-inﬂammatory cytokines such
as tumor necrosis factor (TNF-a), IL-6 and lipidmediators, including
256 B.M.R. Quinto et al. / Cytokine 71 (2015) 255–260platelet activating factor and anti-inﬂammatory IL-10, are produced
early in the course of sepsis [9]. The close relationship between high
levels of inﬂammatory cytokines in plasma and mortality in septic
patients is indicative that the intense activation of inﬂammatory
mediators plays an important role in the development of organ dys-
function [10].
In CRRT, the removal of circulating inﬂammatory mediators is
an attractive strategy, and it seems to be a logical extension of
the therapeutic arsenal already available. While transmembrane
transport by diffusion is dependent on the size of the molecules,
convective transport is independent of particle size, and primarily
depends on the hydraulic permeability and transmembrane water
ﬂow [11].
Several studies have attempted to determine whether the ben-
eﬁcial effect of CRRT in critically ill patients may be partially attrib-
uted to the convective and diffusive removal of pro-inﬂammatory
cytokines, particularly TNF-a and IL-1 [12–15]. However, few and
conﬂicting data exist about the removal of cytokines by CRRT in
septic patients with AKI. The aim of this study was to determine
whether and to what extent the removal of inﬂammatory cyto-
kines by CRRT, speciﬁcally CVVHDF, impacts ICU mortality.2. Materials and methods
2.1. Patients
The study population consisted of 64 patients admitted to the
intensive care unit (ICU) of Hospital Israelita Albert Einstein (São
Paulo, Brazil), who had AKI and required CRRT, speciﬁcally
CVVHDF.
Acute Physiology and Chronic Healthy Evaluation (APACHE II)
was routinely used as the severity of disease score [16] and was
evaluated on admission at ICU and on the day of CVVHDF initia-
tion. All patients were enrolled into this study under informed con-
sent guidelines approved by the Investigation Review Boards of the
Hospital. For comparison, we used a control group of ﬁfteen criti-
cally ill patients without AKI.
Baseline demographic and clinical data were obtained from the
patients’ hospital records.
The following criteria were used for eligibility: age over
18 years; admission to the ICU; fulﬁllment of the AKIN criteria
(Acute Kidney Injury Network) for AKI, as deﬁned: (a) serum creat-
inine increased 0.3 mg/dL or increased 1.5–2.0-fold from baseline
or serum creatinine increased >2.0–3.0-fold from baseline or
serum creatinine increased >3.0-fold from baseline or serum creat-
inine (P4.0 mg/dL) with an acute increase of at least 0.5 mg/dL or
needed for RRT [17], or the calculated baseline creatinine for the
individual according to the MDRD formula (Modiﬁcation of Diet
in Renal Disease) [18] and (b) elevation of at least 0.5 mg/dL com-
pared to baseline creatinine at levels of up to 4 mg/dL; and indica-
tion of CVVHDF. Exclusion criteria were: past history of RRT, renal
transplantation, previous participation in this study, or a DNR (do
not resuscitate) order.2.2. CVVHDF procedure
CVVHDF was conducted using a PrismaM100machine (Gambro
Renal Products, France). As previously described by our group, it
was equipped with an AN 69 hemo ﬁlter, which was primed with
1 L of normal saline containing 5000 IU heparin followed by a sec-
ond prime with only normal saline. Vascular access was provided
by the insertion of a triple lumen catheter (Arrow International,
PA) into either the internal jugular or femoral vein. Blood ﬂow
was constant at 100 mL/min. Four percent tri-sodium citrate was
infused in the arterial line (through a three-way stopcock) andcalcium replacement (0.75% CaCl2) was done by infusion into the
third lumen of the dialysis catheter, beginning with a ﬂow rate of
140 and 70 mL/h, respectively. The dialysis solution was composed
of 110 mEq/L sodium, 111.5 mEq/L chloride, 1.5 mEq/L magne-
sium, and 0.1% dextrose. Sodium bicarbonate (about 20–30 mEq/
L) and potassium phosphate were added to the solution according
to need, with a ﬁnal sodium concentration between 130 and
140 mEq/L. The replacement solution (post-ﬁlter replacement)
was composed of 0.45% NaCl, while 20% NaCl (about 10–15 mL/L)
and 10% magnesium sulfate were added according to need, with
a ﬁnal sodium concentration between 111 and 128 mEq/L. The
bags were carefully mixed in the hospital´s pharmacy [19].
The efﬁcacy of the ﬁlter was measured by the efﬂuent urea con-
centration/pre-ﬁlter urea concentration ratio.
2.3. Blood sampling
2.3.1. Patients
Blood samples collection (40 mL) was performed of ﬁlter inlet
and outlet blood at times 0, 6 and 24 h with the machine in oper-
ation and the ultraﬁltrate collection were drawn at 6 and 24 h at
the time with the change in volume of 2000 ml ± 1000 ml (this vol-
ume of ultraﬁltrate was collected in 40 ± 20 min). All samples were
immediately transported on ice to the laboratory, where they were
centrifuged at 3000 rpm for 10 min, frozen and stored at 70 C
until assay. Samples were collected in the ﬁrst 24 h of CVVHDF.
2.3.2. Healthy volunteers (control group)
We collected 10 mL of whole blood from 35 healthy volunteers.
After collection, the specimens were immediately centrifuged at
4 C and 3000 rpm for 10 min, and samples of separated plasma
were stored as 0.5-mL aliquots at 80 C.
2.3.3. Critically ill patients not undergoing CVVHDF (critically ill
control group)
We collected 10 mL of whole blood from 20 critically ill patients
not undergoing CVVHDF which were held consecutively at times 0,
6 and 24 h after admission and presented an APACHE score of
23.5 ± 4.9. This collection was performed after collection of the
64 patients chosen for this study. After collection, the specimens
were immediately centrifuged at 4 C and 3000 rpm for 10 min,
and samples of separated plasma were stored as 0.5-mL aliquots
at 80 C.
2.4. Biochemical methods
Renal function was evaluated by serum urea, creatinine, sodium
and potassium using standard auto-analyzer techniques [20–23].
The C-reactive protein (CRP) was measured by the immune tur-
bidimetry technique [24], and leukocytes were counted automati-
cally in a CELL DYN 3200 (ABBOTT).
2.5. Cytokine analyses
Plasma levels of C3a were measured with the enzyme immuno-
assay kit C3aHuman September ELISA (BD Pharmingen) following
the manufacturer’s recommendations.
Plasma levels of the inﬂammatory mediators TNFRI and sTNFRII
were measured with the enzyme immunoassay kit (ELISA) follow-
ing the manufacturer’s recommendations (Quantikine R&D Sys-
tems). The levels of TNF-a, IL-10, IL-6 and IL-1b were measured
using high sensitivity kits (Quantikine high sensitivity – R&D Sys-
tems). The levels of inﬂammatory mediators were also measured in
the ultraﬁltrate as described above. The absorbance readings were
measured using a spectrophotometer at 450 nm, and the results
expressed in pg/mL.
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ering the adsorbed amount, was calculated as follows:
Total efﬂuent volume per patient (dialysate bath + ultraﬁltrate
volume + replacement solution, mL/h)  60 min = (mL/
min)  concentration of cytokine (pg/mL) = estimated mass
removed (pg/mL/min).
2.6. Statistical analysis
The results were expressed as mean ± standard deviation (SD)
or as inter-tertile ranges (ITR) when appropriate. The Pearson
chi-square or Fisher exact tests were employed to compare cate-
gorical variables between groups. The levels of all inﬂammatory
markers (TNF-a, sTNFRI, sTNFRII, C3a, IL-6, IL-1b and IL-10) were
converted to logarithms (log) due to their skewed pattern, and
then, we used the student t-test for comparison of variables
between two groups. Analysis of different times of CVVHDF (0, 6
and 24 h) was assessed by analysis of variance (ANOVA) plus Bon-
ferroni. Binary logistic regression analysis was used to determine
independent predictors of mortality. The signiﬁcance level was
set at p < 0.05 or 5%. All analyses were performed using SPSS 21.0.
3. Results
Sixty-four patients underwent CVVHDF and 20 non-dialysis
critically ill patients were included in the study. The demographic
and clinical characteristics of both groups are summarized in
Table 1. In the group of dialysis patients, mean age was
63.2 ± 18.5 years, 67.2% were men and 87.3% were Caucasians.
Regarding the non-dialysis critically ill patients, 66.7% were men,
mean age was 70.1 ± 18.2 years and 80% were Caucasians.
For the purpose of this analysis, we used only the ﬁrst ﬁlter
(ﬁrst 24 h of CVVHDF) per patient for a total of 64 ﬁlters, without
replacement. The average dialysis dose determined for each
patient was 40.8 ± 7.8 (mL/kg/h) and the ﬁlter patency after 24 h
of dialysis was 90.5 ± 4.2 (%) (Table 2). There were no statistically
signiﬁcant differences in the CVVHDF parameters evaluated
between survivors and non-survivors.Table 1
Demographic and outcome parameters of critically ill patients and severely ill
controls.
CVVHDF
patients
Non-dialysis ICU
patients
P
value
Age (years) 63.2 ± 18.5 70.1 ± 18.2 Ns
Men % 67.2 66.7 Ns
White % 87.3 80 Ns
APACHE II score 21.5 ± 9.0 23.5 ± 4.9 Ns
Mortality % 66.3 ± 24.1 44.5 ± 14.8 <0.001
Sepsis % 54.7 53.3 Ns
Clinical % 34.4 20 Ns
Surgical % 9.4 26.7 Ns
Pancreatitis % 1.6 – Ns
ICU admission
Creatinine (mg/dL) 2.1 ± 1.6 1.1 ± 0.5 <0.05
Urea (mg/dL) 79.7 ± 51.0 45.8 ± 28.1 <0.05
Lactate (mmol/L) 23.1 ± 16.9 13.4 ± 8.15 Ns
CRP (mg/L) 29.+6 ± 47.0 11.1 ± 9.6 Ns
Leukocytes (cells/
mL)
11,097 ± 9874 12,379 ± 5678 Ns
After 24 h of CVVHDF
Creatinine (mg/dL) 1.7 ± 0.9 1.2 ± 0.5 Ns
Urea (mg/dL) 56.7 ± 30.8 62.2 ± 51.3 <0.05
Lactate (mmol/L) 24.6 ± 25.5 14.2 ± 18.2 <0.05
CRP (mg/L) 16.1 ± 11.3 6.9 ± 6.4 Ns
Leukocytes (cells/
mL)
12,876 ± 7722 12,331 ± 4732 NsAs depicted in Table 3, at the beginning of CVVHDF, 35 patients
had sepsis (54.7%), 82.8% received vasoactive drugs and 93.8% were
mechanically ventilated. Mean APACHE II score was 32.2 ± 7.1. Of
the 64 patients evaluated, 35 patients (54.7%) died. Comparing
non-survivors with the group of survivors, we observed a higher
incidence of sepsis (68.6 versus 37.9%, p < 0.05), mean APACHE II
score (34.8 ± 7.6 versus 29.2 ± 7.1, p < 0.05) and lactate level
(23.2 ± 17.6 versus 16.4 ± 6.6 mmol/L, p < 0.05).
Critically ill patients who underwent CVVHDF showed higher
serum levels of TNF-a, IL-6, sTNFR1 and sTNFR2 in comparison
with severely ill patients without dialysis (p < 0.005) (data not
shown).
As shown in Table 4, 6 h after CVVHDF, serum C3a levels
decreased in comparison with the beginning of dialysis
(6340 ± 1004 versus 5627 ± 1127, p < 0.05). At 24 h after CVVHDF,
sTNRI and sTNRII levels increased, while there was no difference in
IL-10, IL-6 and IL-1b levels.
In Table 5 we demonstrated the cytokines serum concentrations
of non-dialysis ICU patients.
Baseline characteristics between patients were analyzed
according to the inter-tertile range of TNF-a clearance (ITR1
(<0.54); ITR2 (0.54–2.93); ITR3 (>2.93)) as presented in Table 6.
Serum levels of cytokines measured inlet were not different
between the ITRs analyzed.
In examining mortality, we found that 61.5% of patients who
died had a low clearance of TNF-a during ICU stay, demonstrating
that patients with higher TNF-a removal by CRRT (ITR3) had a bet-
ter survival rate (Table 7). Overall, in spite of this outcome, the fea-
tures between patients with low (<0.54 pg) and high (2.93–
5.27 pg) TNF-a removed amount were not signiﬁcantly different.
It is noteworthy that the removal of the other cytokines studied
had no impact on the outcomes of patients.
Table 8 shows the results of multivariable analysis, the clear-
ance of TNF-a remained independently associated with high mor-
tality after adjustment for sex, age, use of vasoactive drugs,
APACHE II score, sepsis, creatinine and lactate (HR: 0.179, 95% IC:
0.049–0.661, p < 0.01).
4. Discussion
In this study, we evaluated the impact of removing inﬂamma-
tory cytokines by CVVHDF in ICU patients. As expected, according
to APACHE criteria, we observed that at the beginning of CVVHDF,
patients had higher APACHE II scores compared with non-dialysis
ICU patients. It has been reported that patients with AKI requiring
renal replacement therapy have mortality rates as high as 60% [25]
and that for patients undergoing CRRT hospital mortality rates can
range from 44% to 80% [19,26–28]. In fact, we observed that the
expected mortality in patients at the beginning of dialysis was sig-
niﬁcantly higher than in non-dialysis ICU patients (66.3 ± 24.1 ver-
sus 44.5 ± 14.8). Additionally, patients who underwent CVVHDF
were more prone to be under mechanical ventilation and using
vasoactive drugs. In agreement, several studies support that this
clinical condition is predictive of a negative outcome in patients
with AKI, reﬂecting an increased severity of illness that could be
mediated by cardiovascular side effects of AKI or increased cardio-
vascular instability during RRT, as reported by Metnitz et al. [2].
The efﬂuent dose used in the present study was 40.8 mL/kg/h
corrected by the ratio efﬂuent urea concentration/preﬁlter urea
concentration, where it was comparable to that used in the litera-
ture [29]. In fact, we had previously published a retrospective
cohort study with 143 patients with AKI subjected to citrate-based
CVVHDF using an efﬂuent dose of 36.6 mL/kg/h [19]. Additionally,
Honore et al. suggested that a dose of 35 ml/kg/h should remain
the standard dose in septic AKI, particularly in the presence of
shock.
Table 2
CVVHDF parameters.
Parameter Total Survivors Non survivors P
Treatment (h) 1536
Filters 64
Blood ﬂow (mL/min) 100
Dialysis dose (mL/kg/h) 40.8 ± 7.8 42.5 ± 6.5 38.6 ± 9.7 Ns
Filter efﬁcacy at 6 h CVVHDF 0.93 ± 0.03 0.93 ± 0.03 0.93 ± 0.03 Ns
Filter efﬁcacy at 24 h CVVHDF 0.91 ± 0.04 0.90 ± 0.003 0.91 ± 0.05 Ns
Table 3
Clinical and demographic parameters at admission of critically ill patients at the beginning of CVVHDF according to survival.
Total (N = 64) Survivors (N = 29) Non-survivors (N = 35) P value*
Age 63.2 ± 18.5 57.4 ± 17.9 68.05 ± 17.5 <0.05
Men % 67.2 65.5 68.6 Ns
White % 87.3 82.8 91.2 Ns
Sepsis % 54.7 37.9 68.6 <0.05
Clinical % 34.4 44.8 23.5 <0.05
Surgical % 9.3 13.8 7.9 Ns
Pancreatitis % 1.6 3.4 – Ns
APACHE II score 32.2 ± 7.1 29.2 ± 7.1 34.8 ± 7.6 <0.005
Vasoactive drugs 82.8 79.3 85.7 Ns
Creatinine (mg/dL) 3.1 ± 1.7 3.4 ± 1.9 2.8 ± 1.5 Ns
Urea (mg/dL) 127 ± 57.2 135 ± 57.1 119 ± 57.2 Ns
Lactate (mmol/L) 20.1 ± 14.1 16.4 ± 6.6 23.2 ± 17.6 <0.05
CRP (mg/L) 29.6 ± 47.2 46.5 ± 66.5 14.9 ± 9.5 Ns
Leukocytes (cells/mL) 11,097 ± 9871 11,542 ± 13,246 10,731 ± 6020 Ns
Mechanical ventilation 93.8 93.1 94.3 Ns
* Survivors  nonsurvivors.
Table 4
Serum levels of TNF-a, sTNFRI, sTNFRII, sFas, IL-1b, IL-6, IL-10 and C3a in patients with AKI under CVVHDF (N = 64).
0 h 6 h 24 h
Pre Post Pre Post Pre Post
TNF-a (pg/mL) 16.8 ± 12.4 11.7 ± 9.0* 12.3 ± 9.8* 10.7 ± 8.4 13.4 ± 10.7 13.3 ± 12.1##
sFas (pg/mL) 3916 ± 1947 3528 ± 1937* 4056 ± 1964 3998 ± 2043 4671 ± 2251 5141 ± 2335*,##
IL-10 (pg/mL) 32 ± 26 26 ± 23* 29 ± 23 30 ± 23 30 ± 24 29 ± 24
sTNFRI (pg/mL) 11,676 ± 6505 10,693 ± 6262* 11,819 ± 6326 12,023 ± 7553 12,637 ± 7962 14,550 ± 7962*,##
sTNFRII (pg/mL) 8567 ± 5975 8387 ± 6030 8581 ± 6189 8957 ± 6647 9358 ± 6916 10,018 + 7315*,##
IL-6 (pg/mL) 565 ± 554 587 ± 559* 593 ± 565 539 ± 570 579 ± 564 558 + 537
IL1-b (pg/mL) 2.1 ± 2.2 2.3 ± 2.3 1.7 ± 2.1 2.1 ± 2.3* 1.6 ± 2.1 1.8 + 2.3
C3a (pg/mL) 6340 ± 1004 6245 ± 1731* 6242 ± 1730 5627 ± 1127# Na Na
* Post-ﬁlter– pre-ﬁlter, p < 0.05.
# Post-ﬁlter (6 h)– from the beginning of dialysis (0 h), p < 0.05.
## Post-ﬁlter 24 h– from the beginning of dialysis, p < 0.05.
Table 5
Cytokines seric concentrations of non-dialysis ICU patients (n = 20).
Non-dialysis ICU patients
pg/mL 0 h 6 h 24 h
TNF-a 6.7 ± 6.5 7.4 ± 7.7 7.4 ± 5.4
sFas 1849 ± 1185 2386 ± 1911 2301 ± 1489
IL-10 24.1 ± 20 23.4 ± 17 21.6 ± 21.6
sTNFRI 2335 ± 1142 2050 ± 1117 1800 ± 1025
sTNFRII 4321 ± 3767 4368 ± 4360 3779 ± 4723
IL-6 61.6 ± 71.7 68.5 ± 63.9 65.8 ± 59.9
IL1-b 0.03 ± 0.07 0.113 ± 0.244 0.077 ± 0.16
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intensive care), which compared hemoﬁltration doses of 35 ml/kg/
h versus 70 ml/kg/h in critically ill patients with sepsis-induced
shock, AKI, and multiple organ failure, it was observed low overall
mortality (39% at 28 days and 52% at 90 days). In fact, Joannes-Boy-
au and Honore suggested that this may be due to the earlier start of
treatment at the renal injury level. It is known that the IVOIRE studywas interrupted early due to the difﬁculty in recruiting patients. In
the original study there are no reports of cytokines removal by
extra-corporeal system.
High levels of pro-inﬂammatory cytokines have been reported
to be associated with increased mortality in AKI [30]. Chertow
and cols, reported that AKI is a common, early and severe organ
dysfunction during sepsis. Indeed, in the course of sepsis cytokines,
besides being signiﬁcantly increased, initiate a variety of signaling
inﬂuencing the development of AKI. In fact, Simmons et al. found
that the levels of pro-inﬂammatory cytokines were increased when
AKI was coupled with sepsis in comparison with sepsis alone [31].
Because the most frequent etiology of AKI in this study was sepsis,
our patients were expected to have higher levels of circulating pro-
inﬂammatory and anti-inﬂammatory cytokines. In fact, our results
demonstrated that serum levels of the inﬂammatory cytokines
TNF-a, IL-10, sTNFRI and sTNFRII in patients under CVVHDF were
higher when compared with non-dialysis critically ill patients.
Simmons et al. also demonstrated that several cytokines, including
pro-inﬂammatory and anti-inﬂammatory cascades, were elevated
Table 6
Clinical and demographic parameters of critically ill patients in early CVVHDF according to TNF-a removed amount tertiles.
TNF-a removed amount
ITR 1st ITR 2nd ITR 3rd P value
(<0.54) (0.54–2.93) (>2.93)
Age (years) 65.7 ± 17.4 61.6 ± 20.5 61.5 ± 18.2 Ns
Men % 61.5 76.5 66.7 Ns
Body weight (kg) 76.57 ± 13.02 71.57 ± 15.79 73.50 ± 14.84 Ns
BMI 26.77 ± 3.69 24.94 ± 4.44 26.01 ± 5.41 Ns
Clinical and laboratory parameters at the beginning of CVVHDF
APACHE II score 32.4 ± 10.7 32.4 ± 6.5 31.8 ± 4.1 Ns
Creatinine (mg/mL) 2.6 ± 1.4 3.7 ± 2.1 3.2 ± 1.4 Ns
Urea (mg/mL) 112 ± 59.6 157 ± 58.5* 118 ± 44.2 <0.05
Leukocytes (cells/mL) 11.770 ± 6266 9119 ± 4706 11.804 ± 15.467 Ns
CRP (mg/L) 13.7 ± 10.5 18.5 ± 15.5 51.7 ± 71.1 Ns
Lactate (mmol/mL) 22.7 ± 19.6 20.2 ± 9.9 16.6 ± 7.01 Ns
Sepsis % 57.7 52.8 52.4 Ns
Mechanical ventilation % 92.3 100.0 90.5 Ns
Vasoactive drugs % 84.6 76.5 85.7 Ns
IL-10 depuration log 2.1 ± 0.8 2.4 ± 0.6 2.2 ± 0.6 Ns
IL-6 depuration log 2.2 ± 0.9 2.5 ± 0.7 2.4 ± 0.6 Ns
sTNFR1 depuration log 3.4 ± 0.8 3.7 ± 0.3 3.5 ± 0.4 Ns
sTNFR2 depuration log 2.3 ± 0.7 2.6 ± 0.5 2.5 ± 0.5 Ns
TNF-a serum level (pg/mL) 15.6 ± 9.3 12.4 ± 11.6 21.8 ± 15.6 Ns
IL-10 serum level (pg/mL) 39.0 ± 28.8 22.8 ± 17.9 30.4 ± 24.0 Ns
IL-6 serum level (pg/mL) 518 ± 584 405 ± 444 647 ± 624 Ns
sTNFR1 serum level (pg/mL) 12.339 ± 8024 12.222 ± 5345 10.411 ± 5214 Ns
sTNFR2 serum level (pg/mL) 9528 ± 6697 8902 ± 5855 7093 ± 5044 Ns
ITR: inter-tertile range.
* Versus 1st ITR.
Table 7
Critically ill patients under CVVHDF outcomes according to TNF-a removed amount
tertiles.
TNF-a removed amount
ITR 1st ITR 3rd P value
(<0.54) (>2.93)
Outcomes
Death in ICU % 61.5 28.6* 0.039
Death during hospitalization % 73.1 38.1* 0.016
CKD conservative treatment % 11.5 30.0* <0.05
ESRD terminal in hemodialysis % 7.7 30.0* <0.05
Total recovery of renal function % 7.7 5.0 Ns
ITR: inter-tertile range.
* Versus 1st ITR.
Table 8
Mortality prediction and TNF-a removed amount rate on CVVHDF.
HR 95% CI P
value
ITR 3* of TNF-a removed amount
Unadjusted 0.179 0.049–
0.661
0.010
Adjusted for sex and age 0.157 0.038–
0.650
0.011
Adjusted for sex, age and vasoactive drugs 0.153 0.036–
0.646
0.011
Adjusted for sex, age, vasoactive drugs and
APACHE II score
0.165 0.038–
0.717
0.016
Adjusted for sex, age, vasoactive drugs, APACHE II
score and sepsis
0.168 0.038–
0.745
0.019
Adjusted for sex, age, vasoactive drugs, APACHE II
score, sepsis and creatinine
0.165 0.036–
0.767
0.022
Adjusted for sex, age, vasoactive drugs, APACHE II
score, sepsis, creatinine and lactate
0.185 0.038–
0.897
0.036
* ITR 3: TNF-a removed amount > 2.93.
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those subjects who survived [31].The treatment of AKI in intensive care has changed greatly in
recent years. The continuous methods represent a major advance
in the handling of patients, mainly due to the great advantage of
an improved hemodynamic stability, removal of inﬂammatory
cytokines and an effective nutritional support, but recent studies
have still not demonstrated an increased survival with more
intense continuous hemodialysis compared with less intense dial-
ysis [32]. The use of CVVHDF modality intends to hold a diffusive
and convective clearance for low and medium weight substances
depuration. To date, there is no consensus on when to start the
procedure and what the best course of CRRT to be use. Bernard
Page et al. describe the use of early CRRT procedure by CVVHDF,
and suggest that this method can improve survival in patients
who have a poor prognosis.
The main difference between CVVHDF and intermittent hemod-
ialysis is the use of physical–chemical diffusion and convection of
solutes to remove for puriﬁcation of uremic blood and the possibil-
ity of removal inﬂammatory substances. According to Metnitz et al.
the type of hemoﬁlter membrane used in extracorporeal treatment
is an important factor implicated in the prognosis of patients with
AKI [2]. The biocompatibility of a hemodialysis membrane is
deﬁned by the absence of complement system activation [33]. Such
membranes in contact with blood can activate the complement
system resulting in changes in leukocyte and platelet counts
[34,35]. Our results showed that even though levels of IL-10, sFas,
sTNFRI and sTNFRII increased after 24 h of CVVHDF, the C3a levels
remained unchanged, suggesting that the dialysis membrane used
in this study was biocompatible and did not cause complement
activation. This situation may have been determined by the clinical
severity of the patient [34]. It is possible that sFas, an additional
marker of inﬂammation seen in patients with AKI; or even that
may be an increase in its synthesis to counteract the cellular injury
that is observed in the LRA. Recently, it was reported that TNF-
shock models, such as sepsis, have suggested that RipK1 and RipK3
may be involved in TNF-induced signaling endothelial cells sug-
gesting the role of necroptosis in acute pathophysiological process.
Moreover, the production’s behavior of endogenous and exogenous
260 B.M.R. Quinto et al. / Cytokine 71 (2015) 255–260cytokines clearances, in this situation, is unpredictable. Its possible
that the removal of TNF-a is more effective in the ﬁrst 6 h of treat-
ment with CVVHDF, and this may have inﬂuenced the outcome of
patients [36,37].
It is well known that pro-inﬂammatory cytokines such as TNF-
a, IL-1b and IL-6 are released at the beginning of an inﬂammatory
response to infection or tissue damage, and many studies have
shown that plasma cytokine levels predict mortality in critically
ill patients [1,4,38]. Many attempts have been made to blunt
inﬂammatory mediator effects, and despite the evidence above, lit-
tle is known about the impact of the removal of inﬂammatory
mediators by CVVHDF. The most important ﬁnding of our data
was from the analysis according to the inter-tertile range of TNF-
a removed amount. As far as we know, this is the ﬁrst study show-
ing that patients with higher TNF-a removal levels with CVVHDF
treatment (>2.93 pg/min/mL) have a better survival rate. We also
demonstrated that higher amount of removed TNF-a was an inde-
pendent factor associated with lower mortality even after adjust-
ing for variables related to ICU mortality such as sex, age,
vasoactive drugs, APACHE II score, sepsis, creatinine and lactate.
Additionally, because serum cytokine levels were the same in
those who died as in those who did not die, we speculate that
TNF-a removal determines a better survival proﬁle in the ICU.
In conclusion, we showed that lower levels of removed amount
of TNF-a are an independent predictor of mortality in critically ill
patients undergoing CVVHDF. However, further studies are needed
to study the beneﬁcial effect of continuous renal replacement ther-
apy (CVVHDF) in sepsis and inﬂammatory states.
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